Kewaunee Scientific
Designs, manufactures, and installs laboratory furniture, infrastructure, and biosafety equipment.
Something off on this page? Send us feedback.
Profile
It sells laboratory furniture and infrastructure through Lab Products Group and International operations. NuAire adds biosafety cabinets, incubators, and ultralow freezers to the product range.
Designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The Lab Products Group supplies cabinetry, fume hoods, flexible systems, worksurfaces, workstations, and related products, including NuAire biological-safety cabinets, CO2 incubators, and ultralow freezers. Its systems serve laboratory settings requiring coordinated furniture, airflow, and specialized equipment.
International covers non-US operations. Manufacturing is based in Statesville, North Carolina, and Bangalore, India, while sales offices span the United States, India, Saudi Arabia, and Singapore. NuAire broadened the product range, and its distribution partners extend the company's reach beyond the US.
Company facts
Categories
Key statistics
Year to date +0.8% · Average volume (30d) 4.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jun 23, 2026Q4 FY26 | — | $1.14 | — | — | $77.1M | — | −3.63% |
| Mar 11, 2026Q3 FY26 | — | $0.28 | — | — | $69.4M | — | −13.08% |
| Dec 10, 2025Q2 FY26 | — | $0.91 | — | — | $70.1M | — | −4.35% |
| Sep 10, 2025Q1 FY26 | — | $1.10 | — | — | $71.1M | — | −21.23% |
Financial highlights
| 12 quarters | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $67.2M | $77.1M | $71.1M | $70.1M | $69.4M | $71.4M | |
| Gross profit | $18.4M | $24.0M | $20.9M | $19.7M | $18.5M | $21.2M | |
| Operating income | $2.3M | $8.5M | $4.8M | $4.1M | $2.6M | $5.2M | |
| Net income | $1.4M | $4.9M | $3.1M | $2.4M | $692.0K | $3.4M | |
| Diluted EPS | $0.45 | $1.63 | $1.04 | $0.82 | $0.23 | $1.13 | |
| Gross margin | 27.4% | 31.2% | 29.4% | 28.1% | 26.7% | 29.8% | |
| Operating margin | 3.3% | 11.0% | 6.8% | 5.9% | 3.7% | 7.3% |
Fiscal years (4-quarter sums)FY22 $168.9M · FY23 $219.5M · FY24 $203.8M · FY25 $240.5M · FY26 $282.0M
Revenue by product · Q3 FY26
Revenue by geography · Q4 FY26
Balance sheet, Apr 30, 2026Cash & short-term investments $11.6M · Total debt $30.2M · Total assets $178.3M · Shareholders' equity $74.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 2.87M · Float 2.13M · 74.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Northern Trust Corp | 246.0K | 8.57% | 13F | May 14, 2026 |
| Zucker Anita G | 193.9K | 6.80% | 13D | Feb 5, 2025 |
| Dimensional Fund Advisors LP | 177.3K | 6.18% | 13F | May 7, 2026 |
| Minerva Advisors LLC | 149.4K | 5.20% | 13G | Jun 29, 2026 |
| Vanguard Capital Management LLC | 112.5K | 3.92% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 7, 2026 | Thomas David Iii Hull | director, officer: President, CEO | −2,177 | $37.50 |
| Jan 6, 2026 | Donald T. III Gardner | officer: Chief Financial Officer | −2,000 | $37.57 |
| Dec 31, 2025 | Thomas David Iii Hull | director, officer: President, CEO | −629 | $37.66 |
| Dec 30, 2025 | Thomas David Iii Hull | director, officer: President, CEO | −29 | $38.00 |
| Dec 29, 2025 | Thomas David Iii Hull | director, officer: President, CEO | −884 | $38.01 |
Peers
- Thermo Fisher Scientific
Broad lab-equipment rival in biosafety cabinets and ULT freezers
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific | $37.78 | −0.01% | $108.4M | 11.7 | — | 0.4 | 0.0% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Median | 33.5 | 23.7 | 5.0 | +10.5% |